Strategic partnerships Celon Pharma has recent collaboration activity with Mabion SA and Pharmalink Drug Store, signaling openness to co-development, licensing, and distribution deals that leverages their semaglutide based products and next-generation biologics capabilities.

Diabetes focus Financing and manufacturing efforts are directed toward semaglutide production (Reduzek) for type 2 diabetes, including a dedicated manufacturing facility in Slovakia funded with up to EUR 23 million, presenting a clear entry point for sales of manufacturing capacity, formulation services, or supply chain support.

R&D strength A robust internal R&D team of over 60 scientists with a strong emphasis on oncology, inflammatory and metabolic diseases creates opportunities to license or co-develop early to mid-stage assets, as well as provide research services or contract development.

Growth funding Recent loan financing from the European Bank for Reconstruction and Development indicates capacity to scale manufacturing and operations, suggesting readiness for supplier partnerships, equipment upgrades, and technology deployment to expand production capabilities.

Industry recognition Recognition as Diamonds of Innovation and active presence at major conferences (APA 2025) highlight credibility and visibility in pharma/biotech spaces, enabling outreach to potential customers, co-developers, and distributors seeking reputable partners.